Tvardi Therapeutics (TVRD) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Tvardi Therapeutics (TVRD) is Strong Underperform.

The composite score behind that read is -0.51, weighing +0.03 of bullish evidence against -0.52 bearish.

Tvardi Therapeutics last closed at $1.08, -5.26% on the session.

Against the IVW growth benchmark the position is -5.87% over the forecast window.

The read is built from 12 underlying insights — 1 bullish and 11 bearish.

Agreement across those insights is 92%.

17 graded predictions for TVRD so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Tvardi Therapeutics in the 8th percentile on return on equity, where 100 is best.

Tvardi Therapeutics is classified under Health Care / Pharmaceuticals, with a market capitalisation of $15.21M.

StockMap tracks Tvardi Therapeutics as the 119th largest of the 142 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 61 Moderate Underperform, 57 Neutral, 19 Strong Underperform and 5 Moderate Outperform.

On that composite Tvardi Therapeutics ranks 127th of 142 in the group, against a group median of -0.24.